PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis.

Abstract This study systemically evaluated the efficacy and safety of intermittent intravenous pulse therapy with different doses of cyclophosphamide (CTX) for the treatment of lupus nephritis (LN).
PMID
Related Publications

Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.

Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis .

The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.

Treatment for lupus nephritis.

Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29390559
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20180212
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 51
DP  - 2017 Dec
TI  - Systematic evaluation of different doses of cyclophosphamide induction therapy
      for lupus nephritis.
PG  - e9408
LID - 10.1097/MD.0000000000009408 [doi]
AB  - OBJECTIVE: This study systemically evaluated the efficacy and safety of
      intermittent intravenous pulse therapy with different doses of cyclophosphamide
      (CTX) for the treatment of lupus nephritis (LN). METHODS: We screened the Chinese
      Journal Full-text Database (CNKI, 1994-present), China Biology Medicine (CBMdisc,
      1978-present), VIP Database for Chinese Technical Periodicals (1989-present),
      PubMed (1948-present), MEDLINE (Ovid SP, 1946-present), Embase (1947-present),
      and the Cochrane controlled trials register (13, 2017). Literature reports were
      selected according to the inclusion and exclusion criteria, effective data were
      extracted, research quality was evaluated, and RevMan5.2 was used for
      meta-analysis. RESULTS: Seven randomized controlled studies were included,
      consisting of 655 patients. The meta-analysis results showed no significant
      differences between the low- and high-dose cyclophosphamide groups in partial,
      complete, and total remission rates as well Systemic Lupus Erythematosus Disease 
      Activity Index (SLEDAI). Furthermore, there were no significant differences
      between the 2 groups in hematologic toxicity and gastrointestinal reaction, but
      the risk of infection (risk ratio [RR] = 0.74, 95% confidence interval [CI],
      0.56-0.98, total effect inspection Z = 2.12, P = .03), and menstrual disorder (RR
      = 0.46, 95% CI, 0.31-0.69, total effect inspection Z = 3.83, P = .0001) decreased
      in the low-dose cyclophosphamide group. CONCLUSIONS: There was no obvious
      difference between the low- and high-dose cyclophosphamide groups in efficacy in 
      the treatment of lupus nephritis, but the risk of infection and menstrual
      disorder significantly decreased in the low-dose group.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Tian, Ming
AU  - Tian M
AD  - Department of Nephrology, Puai Hospital.
FAU - Song, Xiaohong
AU  - Song X
AD  - Department of Nephrology, Puai Hospital.
FAU - Dong, Liping
AU  - Dong L
AD  - Department of Nephrology, Puai Hospital.
FAU - Xin, Xing
AU  - Xin X
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, Hubei, P.R.China.
FAU - Dong, Junwu
AU  - Dong J
AD  - Department of Nephrology, Puai Hospital.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - AIM
SB  - IM
MH  - Cyclophosphamide/*administration & dosage/therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage/therapeutic use
MH  - Infusions, Intravenous/methods
MH  - Lupus Nephritis/*drug therapy
MH  - Pulse Therapy, Drug/methods
MH  - Treatment Outcome
PMC - PMC5758261
EDAT- 2018/02/03 06:00
MHDA- 2018/02/13 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1097/MD.0000000000009408 [doi]
AID - 00005792-201712220-00146 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(51):e9408. doi: 10.1097/MD.0000000000009408.